MCM
ACOR

Matarin Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Matarin Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,134
Closed -$2.12M – 289
2018
Q4 		$2.12M Sell
1,134
-173
-13% -$376K 0.17% 172
2018
Q3 		$3.08M Sell
1,307
-33
-2% -$102K 0.2% 156
2018
Q2 		$4.62M Buy
1,340
+448
+50% +$1.37M 0.33% 105
2018
Q1 		$2.53M Buy
892
+136
+18% +$407K 0.19% 160
2017
Q4 		$1.95M Buy
+756
New +$2.15M 0.15% 170
2013
Q3 		– Sell
-37
Closed -$145K – 216
2013
Q2 		$145K Buy
+37
New +$152K 0.15% 179

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Matarin Capital Management's ACOR Position: Q1 2019 in Review

Matarin Capital Management sold out of Acorda Therapeutics (ACOR) in Q1 2019, closing a stake of 1,134 shares — an estimated $2.12M sold.

Matarin Capital Management first reported a position in ACOR in Q2 2013 and held it in 6 quarters. The position peaked at $4.62M in Q2 2018. 184 funds tracked by Wall St. Rank hold ACOR as of Q1 2019.

  • Matarin Capital Management reported no remaining Acorda Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Matarin Capital Management sold 1,134 Acorda Therapeutics shares in Q1 2019, an estimated $2.12M.
  • Matarin Capital Management first reported a position in Acorda Therapeutics in Q2 2013 and held it in 6 quarters.
  • Matarin Capital Management's Acorda Therapeutics position peaked at $4.62M in Q2 2018.
  • 184 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2019.

Based on Matarin Capital Management's 13F filing for Q1 2019, filed 24 Apr 2019.